U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. 7 Daze, LLC - 552809 - 05/01/2018
  1. Warning Letters

WARNING LETTER

7 Daze, LLC MARCS-CMS 552809 —


Recipient:
Recipient Name
John Lau
7 Daze, LLC

13170 Spring Street
Baldwin Park, CA 91706
United States

Issuing Office:
Center for Tobacco Products

United States


 HHS logo                                   HHS logo

DEPARTMENT OF HEALTH 
AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
SILVER SPRING, MD 20993
UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
BUREAU OF CONSUMER PROTECTION
WASHINGTON, D.C. 20580

 

May 1, 2018
 
VIA UPS and Electronic Mail
 
John Lau
7 Daze, LLC
13170 Spring Street
Baldwin Park, CA 91706-2284
info@7dazemfg.com
 
WARNING LETTER
 
Dear John Lau:
 
This is to advise you that the Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) and the U.S. Federal Trade Commission (FTC) recently reviewed the website http://7dazemfg.com from which you take orders for the Pink Sticks e-liquid product. FDA has determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), as amended by the Family Smoking Prevention and Tobacco Control Act, these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)). In addition, the FTC reviewed your marketing for Pink Sticks e-liquid under Section 5 of the FTC Act, 15 U.S.C. § 45(a).
           
FD&C Act Misbranding Violation 
 
FDA has determined that your Pink Sticks e-liquid is misbranded under section 903(a)(1) of the FD&C Act (21 U.S.C. § 387c(a)(1)) and/or section 903(a)(7)(A) of the FD&C Act (21 U.S.C. § 387c(a)(7)(A)) because its labeling and/or advertising is false or misleading.
 
FDA’s investigation of the website http://7dazemfg.com revealed that it sells or distributes Pink Sticks e-liquid with labeling and/or advertising that causes it to imitate food products, particularly ones that are marketed toward, and/or appealing to, children (see Exhibit A). Specifically, the labeling and/or advertising of the product looks very similar to Pocky Strawberry biscuit sticks (see Exhibit B), a product that is marketed toward, and appealing to, children. For example, the labeling and/or advertising for Pink Sticks e-liquid includes the appearance of a box of biscuit sticks that is substantially similar to the packages in which biscuit sticks are sold, an image of arrayed biscuit sticks, and a color scheme that is substantially similar to the biscuit stick package in Exhibit B. Also, your website describes Pink Sticks e-liquid as “[d]elicious flavor of ripe strawberries into a sweet pink cream that covers crispy cookie biscuit stick.” Further, Pink Sticks e-liquid has a strong scent like Pocky Strawberry biscuit sticks that is easily detected without opening the package.  This labeling and/or advertising causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children and is therefore misleading.
 
Sticks on Pink box 
 
                                                                                
Children are at particular risk for ingesting e-liquid products with labeling and/or advertising that causes the product to imitate a food or beverage, particularly a food or beverage that is typically marketed toward, and/or appealing to, children. Moreover, children are at particular risk because exposure to the nicotine in the e-liquid product, even in relatively small amounts, could result in acute toxicity. Child poisonings due to the ingestion of liquid nicotine have recently increased substantially.  Severe harms can occur in small children from ingestion of liquid nicotine, including death from cardiac arrest, as well as seizure, coma, and respiratory arrest.
 
Given that the labeling and/or advertising of Pink Sticks e-liquid describes its nicotine content as 6mg/mL, with a total volume of 60mL, an accidental ingestion of slightly less than half a teaspoon would reach the lower end of the fatal dose range for an average two-year-old. Additionally, an accidental ingestion of approximately 2% of a teaspoon would reach the lower end of the non-fatal acute toxicity range for an average two-year-old.
 
The FD&C Act provides, in part, that a tobacco product shall be deemed to be misbranded (1) if its labeling is false or misleading in any particular (section 903(a)(1)), or (2) if the tobacco product is distributed or offered for sale in any State and its advertising is false or misleading in any particular (section 903(a)(7)(A)).  The labeling and/or advertising for Pink Sticks e-liquid is misleading because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. Therefore, the product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act.
 
The FD&C Act violation discussed in this letter does not necessarily constitute an exhaustive list. You should immediately correct the violation that is referenced above, as well as violations that are the same as or similar to the one stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.
 
It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations.  Failure to ensure full compliance with the FD&C Act may result in FDA initiating further action without notice, including, but not limited to, civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. Please note that any adulterated and misbranded tobacco products offered for import into the United States are subject to detention and refusal of admission.
 
Unfair or Deceptive Marketing
 
In addition, the Federal Trade Commission has reviewed the online marketing of Pink Sticks e-liquid. Section 5 of the FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. This prohibition includes practices that present unwarranted health or safety risks. Commission Policy Statement on Unfairness, 104 F.T.C. 1070, 1071 (1984) (appended to Int’l Harvester Co., 104 F.T.C. 949 (1984)), available at https://www.ftc.gov/public-statements/1980/12/ftc-policy-statement-unfairness. Preventing practices that present unwarranted health and safety risks, particularly to children, is one of the Commission’s highest priorities. FTC Strategic Plan for 2018-2022, at 6; Philip Morris, Inc., 82 F.T.C. 16 (1973).
 
As noted above, Pink Sticks e-liquid is marketed in packaging that resembles Pocky Strawberry biscuit sticks. Pink Sticks e-liquid has a scent similar to Pocky Strawberry biscuit sticks and the odor is detectible without opening the packaging. Given the significant number of serious child poisonings due to the ingestion of liquid nicotine, packaging Pink Sticks e-liquid in a manner that is likely to be particularly appealing to young children could present an unwarranted risk to health and safety.
 
The FTC strongly urges you to review your marketing, including packaging, for Pink Sticks e-liquid and similarly marketed products and to take swift and appropriate steps to protect consumers, especially young children.
 
Conclusion and Requested Actions
 
With regard to the FD&C Act violation described in this letter, please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative labeling, advertising, sale, and/or distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you do not believe that your products are in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. You can find the FD&C Act through links on FDA’s homepage at http://www.fda.gov.
 
Please note your reference number, RW1800845, in your response and direct your response to the following address:
 
DPAL-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
c/o Document Control Center
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
 
If you have any questions, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.   
 
With regard to the FTC-related issues described in this letter, please notify Rosemary Rosso of the FTC via electronic mail at rrosso@ftc.gov within 15 days of receipt of his letter of the specific actions you have taken to address the FTC’s concerns.
 
Sincerely,
 
/S/ 
Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
Center for Tobacco Products
 
 
/S/ 
Mary K. Engle
Associate Director
Division of Advertising Practices       
Federal Trade Commission
 
   
 
VIA UPS and Electronic Mail
 
cc:
 
John Lau
7 Daze LLC
1425 S. Vineyard Ave.
Ontario, CA 91761
 
John Lau
7 Daze LLC
7629 Garvalia Ave.
Rosemead, CA 91770
 
WhoisGuard Inc.
64c7f9a8745c4e2a9391e089a1fbe8ab.protect@whoisguard.com
 
NameCheap Inc.
abuse@namecheap.com
 
Shopify Inc.
abuse@shopify.com
 
 

 

Close Out Letter

 
Back to Top